Transforming cancer treatment through precision drug testing
OncoForma is pioneering functional precision oncology — testing actual patient tumors against comprehensive drug panels to predict treatment efficacy before therapy begins.
We're addressing a $150+ billion global oncology market where 40-60% of patients fail first-line therapy, resulting in delayed outcomes, increased healthcare costs, and preventable patient suffering.
Despite advances in genomic testing, oncologists still rely heavily on population-based treatment guidelines. Genomic data identifies mutations but cannot predict functional drug response with certainty, leading to:
OncoForma provides functional drug response data by testing patient-derived tumor organoids against 1,800+ therapies — delivering actionable treatment guidance in 4-6 weeks.
Patient-derived organoid platform that maintains tumor biology and drug response characteristics, combined with high-throughput screening of the broadest drug panel available.
Building evidence through early pilot program with leading oncologists. Accumulating drug-response data for AI model training and clinical validation studies.
Fee-for-service testing transitioning to AI-enabled prediction platform. Clear path from manual testing to automated, scalable precision medicine.
Testing 1,800+ compounds versus competitors' 50-300 drug panels. Comprehensive coverage reveals treatment options others miss.
Saskatchewan-based operations provide 30-40% cost advantage over US competitors while maintaining quality. Enables competitive pricing and superior margins.
Fee-for-service partnership with University of Saskatchewan provides access to world-class facilities without IP entanglement or technology transfer delays.
Every test generates proprietary drug-response data for training predictive AI models. Building a unique dataset that becomes increasingly valuable and defensible over time.
Led by recognized experts in cancer biology, drug discovery, and precision medicine from leading research institutions.
Revenue Model: Fee-for-service organoid drug screening ($8,000-12,000 per test)
Strategy: Validate clinical utility through pilot program with 20-50 patients. Build initial revenue and establish reimbursement pathway.
Milestone: First 50 patients, clinical validation data, payer discussions
Revenue Model: Expand to 200-500 tests annually as evidence builds
Strategy: Publish validation studies, establish partnerships with major cancer centers, secure insurance reimbursement codes.
Milestone: $2-5M ARR, published clinical data, insurance coverage
Revenue Model: AI prediction service ($2,000-4,000 per prediction) with higher margins and instant results
Strategy: Train ML models on accumulated drug-response data. Offer instant treatment predictions from genomic/clinical data alone — no tissue required.
Milestone: AI model validation, 10X unit economics improvement, global scalability
Seeking seed funding to complete clinical validation and scale operations
Complete 50-patient pilot study with outcome data
Establish payer relationships and coverage pathways
Hire clinical liaison and business development
Begin building ML infrastructure and data pipeline
Fee-for-service agreement with University of Saskatchewan's leading cancer research lab
Organoid platform proven with 85%+ success rate for tissue culture
Assembled scientific and clinical advisors from top-tier institutions
Early oncologist interest and pilot program framework established
Interested in learning more about OncoForma's investment opportunity? Complete the form below and we'll send you our detailed pitch deck and financial projections.